The Cardiorenal Connection: Diagnosis & Treatment of CKD Associated with T2D

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

The Cardiorenal Connection: Diagnosis & Treatment of CKD Associated with T2D

Program Information

Program Information

ReachMD Healthcare Image

How do you address the cardiovascular and renal risk that your patients with chronic kidney disease and type 2 diabetes face?

Please see 

Indication and Important Safety Information.

  • Sponsored by

  • Overview

    Patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) are at greater risk of cardiovascular-related death compared to patients with T2D alone, which is why managing this risk is so important. Could the treatment option KERENDIA (finerenone) help these patients with CKD associated with T2D? Join Dr. Norman Lepor as he explores the clinical trial data on this therapy with Dr. Holly Kramer, Professor in the Division of Nephrology and Hypertension and the Co-Director of the Clinical Research Methods and Epidemiology Program at Loyola University Medical Center.

    PP-KER-US-1295-1 12/22 


    KERENDIA® (finerenone) is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D)



    • Concomitant use with strong CYP3A4 inhibitors
    • Patients with adrenal insufficiency


    • Hyperkalemia: KERENDIA can cause hyperkalemia. The risk for developing hyperkalemia increases with decreasing kidney function and is greater in patients with higher baseline potassium levels or other risk factors for hyperkalemia. Measure serum potassium and eGFR in all patients before initiation of treatment with KERENDIA and dose accordingly. Do not initiate KERENDIA if serum potassium is >5.0 mEq/L

    Measure serum potassium periodically during treatment with KERENDIA and adjust dose accordingly. More frequent monitoring may be necessary for patients at risk for hyperkalemia, including those on concomitant medications that impair potassium excretion or increase serum potassium


    • From the pooled data of 2 placebo-controlled studies, the adverse reactions reported in ≥1% of patients on KERENDIA and more frequently than placebo were hyperkalemia (14% vs 6.9%), hypotension (4.6% vs 3.9%), and hyponatremia (1.3% vs 0.7%)


    • Strong CYP3A4 Inhibitors: Concomitant use of KERENDIA with strong CYP3A4 inhibitors is contraindicated. Avoid concomitant intake of grapefruit or grapefruit juice
    • Moderate and Weak CYP3A4 Inhibitors: Monitor serum potassium during drug initiation or dosage adjustment of either KERENDIA or the moderate or weak CYP3A4 inhibitor and adjust KERENDIA dosage as appropriate
    • Strong and Moderate CYP3A4 Inducers: Avoid concomitant use of KERENDIA with strong or moderate CYP3A4 inducers


    • Lactation: Avoid breastfeeding during treatment with KERENDIA and for 1 day after treatment
    • Hepatic Impairment: Avoid use of KERENDIA in patients with severe hepatic impairment (Child Pugh C) and consider additional serum potassium monitoring with moderate hepatic impairment (Child Pugh B)

    Please read the Prescribing Information for KERENDIA.

Schedule8 Feb 2023